Promoting the designation of drugs that are concerned about misuse as GLP1-based obesity treatment drugs such as high costs and operators
Oct 27, 2025
|
These drugs are prescribed to obese patients with an initial body mass index (BMI) of 30kg/㎡ or more, or overweight patients with a BMI of 27kg/㎡ or less than 30kg/㎡ by imitating the action of GLP-1 hormones.
However, even those who are not the original diabetes treatment or highly obese patients are known as 'fat-loss injections', and the number of cases prescribed for cosmetic purposes has increased rapidly, raising concerns about misuse.
Recognizing the seriousness of this, the Ministry of Health and Welfare plans to strengthen the management of the drugs by designating them as drugs of concern about misuse in consultation with the Ministry of Food and Drug Safety.
There are also many concerns about side effects of these obesity drugs, which are prescription drugs. In addition to digestive problems such as mild nausea, vomiting, and diarrhea, fatal complications such as pancreatitis and intestinal obstruction (intestinal paralysis) have been reported.
According to a recent guide released by the Ministry of Food and Drug Safety, if patients taking diabetes drugs use GLP-1-based obesity drugs together, the risk of lowering blood sugar may increase, so they should consult with medical staff on whether to control the dose of the drug. In addition, the use of obesity treatment is prohibited during pregnancy and lactation, and it is recommended to plan pregnancy in consideration of the drug's residual period in the body.
This article was translated by Naver AI translator.
